RFK Jr. 关于肽类药物的担忧:监管政策引发争议
RFK Jr. Is Ushering in Peptides. As an Oncologist, Here Are My Concerns.
作者指出,HHS宣布了一项关于六种未获批准肽类药物的临时执法豁免政策,但缺乏临床证据支持。作者担心这些药物在未充分研究前的广泛使用可能带来风险。
作者对未获批准的肽类药物的监管政策提出担忧,强调需要更多临床证据。
— Clinical evidence hasn't caught up with commercial enthusiasm
by Gilberto de Lima Lopes Junior, MD, MBA
November 10, 2026 • 5 min read
On July 13, 2025, at a Las Vegas hotel hosting the Revolution Against Aging and Death Festival, two women were taken away in ambulances. Both had received injections containing experimental peptides at a conference booth. Both became seriously ill and required ventilators. One mixture was believed to contain MOTS-c, P21, BPC-157, and TB4, substances promoted for tissue repair, metabolic health, and longevity.
Both women recovered. Nevada regulators subsequently imposed $35,000 in fines on four parties involved. But investigators could not establish what caused the reactions. They were unable to obtain the injected products for laboratory testing, and their exact contents remain unverified.
That is what bothers me most: two women experienced life-threatening reactions, and investigators could not determine precisely what they received.
Now, Washington is opening a regulatory path for some of these unproven peptides. On October 28, HHS announced an interim enforcement-discretion policy covering six peptides: BPC-157, MOTS-c, TB-500, KPV, Semax, and Epitalon. Under specified conditions, the government does not intend to take enforcement action against licensed pharmacies and physicians compounding these substances while the FDA considers formal rulemaking.
This is not an FDA approval, and it does not establish safety or effectiveness. While the HHS policy includes safeguards that represent progress, the policy also permits wider access before clinical evidence has caught up with commercial enthusiasm.
The question is not whether peptides have therapeutic potential. Many of them do. The question is whether that potential justifies their use before we know whether they work and are safe. The policy followed a July meeting of the FDA's Pharmacy Compounding Advisory Committee, which voted eight to six with one abstention, to recommend BPC-157 for the compounding list. It also endorsed five of the other six substances considered.
FDA reviewers had reached a different conclusion. Their briefing documents found insufficient evidence to support adding any of the seven substances. For BPC-157, evaluated for ulcerative colitis, they could not establish effectiveness. For several others, including TB-500, KPV, MOTS-c, and Epitalon, human safety studies were absent or extremely limited. Reviewers also identified problems with product characterization.
I have spent much of my career conducting oncology trials, including studies contributing to immunotherapies and targeted agents that are now used worldwide. I have seen promising mechanisms fail to translate into patient benefit and unexpected toxicities emerge after treatments entered routine practice. Clinical development is slow, expensive, and often disappointing. But it is how we distinguish a promising hypothesis from a useful medicine. We should make the review process more efficient, not bypass it.
I see a particular oncologic concern with the premature movement on peptides. Experimental studies suggest BPC-157 may stimulate angiogenesis, the formation of new blood vessels, through pathways involving VEGFR2 and endothelial nitric oxide synthase. Angiogenesis supports normal tissue repair. It is also a process many tumors exploit to sustain growth. This does not mean BPC-157 causes cancer or promotes tumor progression -- we lack human evidence to make that claim. But neither can we definitively exclude such effects, particularly with prolonged exposure or in patients with existing or previously treated malignancies.
In oncology, we routinely encounter treatments acting on pathways shared by normal and malignant tissues. Biological activity beneficial in one setting may have unintended consequences in another. The response should not be to assume harm, but to investigate it.
There is also an indication mismatch. The FDA evaluated BPC-157 for ulcerative colitis, while much commercial interest concerns tendon injuries, exercise recovery, and anti-aging. Evidence for one indication cannot establish safety or effectiveness for another, particularly when doses, routes, and duration differ.
The HHS policy includes safeguards worth acknowledging: appropriately sourced ingredients, documentation of identity and purity, single-ingredient preparations, labeling, serious adverse-event reporting, and patient-specific prescriptions. These address genuine problems in the existing peptide market. Patients already obtain experimental substances through poorly regulated online suppliers. Licensed compounding under defined conditions could reduce some risks.
But we must distinguish between three questions:
- Is the product what it claims to be?
- Is it safe?
- Does it benefit the patient?
Manufacturing controls help answer the first one. Toxicology and clinical studies address the second. Well-designed trials establish the third. A certificate of analysis cannot demonstrate effectiveness. A prescription does not establish a favorable benefit-risk ratio. Adverse-event reporting cannot replace prospective safety studies.
Compounding serves an important clinical purpose, meeting individual needs when commercial formulations are unsuitable. But it should not replace drug development. When experimental peptides are marketed through wellness clinics, telehealth, and social media to thousands of patients for similar purposes, they begin to resemble commercial drugs, even when prescriptions are individualized.
The same principle applies to longevity medicine. Research into cellular senescence, mTOR signaling, metabolic regulation, and cellular reprogramming offers genuine opportunities. I welcome it. But results in mice do not establish human benefit, and widespread use without systematic study does not necessarily generate reliable knowledge. We should accelerate research, not replace it with uncontrolled experimentation.
The HHS policy remains interim, with public comments invited through November 13. That process should address dosing, clinical benefit, long-term safety, adverse-event surveillance, and opportunities to link expanded access to systematic evidence generation.
The choice is not between innovation and regulation. Good regulation enables innovation while protecting patients from uncertain benefits and risks. We have learned this repeatedly in cancer drug development: a compelling mechanism begins a research program. It does not prove a drug is effective.
Innovation deserves encouragement. And patients deserve evidence.
来源:MedPage Today · medpagetoday.com